Evaluate the prevalence of the most typical polymorphic markers of VEGF-A factor: C963T, G405C,-1154 in the patients with nasopharyngeal angiofibroma.
As the object of research was to characterized polymorphic locuses in the human genome, and position of the single-nucleotide polymorphism known there was used opportunity for automatic processing of the result with the software of the devices used. On the basis of relative height of peaks on the pyrogram homo- or heterozygous state was determined by polymorphic locus.
At genotyping of a marker G405С of VEGF-A gene in group of the patients the increase in frequency of prevalence of a genotype CC (40.0 %) was noted, in comparison with control group (15.0 %). In case of research of G-1154A polymorphism the decrease (10.0 %) in prevalence of a genotype AAi, increase in quantity of detection of a genotype GG (50.0 %) in group of the patients with angiofibroma was observed, in comparison with the control (30.0 % and 10.0 %, respectively). The expected frequency of distribution of genotypes on balance of Hardy-Waiberg (BHW) in group of the patients at the analysis of a genetic marker С963T of a gene VEGF-A has made: С/С = 0.49; С/Т = 0.42; Т/Т = 0.09; in group of the control: С/С = 0.56; С/Т = 0.37; Т/Т = 0.06. The observable frequency of distribution of genotypes on BHW in group of the patients was: С/С = 0.55; С/Т = 0.30; Т/Т = 0.15 (χ2 = 1.6; Р = 0.2); in group of the healthy donors: С/С = 0.50; С/Т = 0.50; Т/Т =0.0 (χ2 = 0.1; Р = 2.2).
At the analysis of a genetic marker G405С of a gene VEGF-A the expected frequency of distribution of genotypes by BHW in group of the patients was: G/G = 0.06; G/C = 0.37; C/C = 0.56; in group of the control: G/G = 0.49; G/C = 0.42; C/C = 0.09. The observable frequency of distribution of genotypes in group of the patients was: G/G = 0.05; G/C = 0.40; C/C = 0.55 (χ 2 = 0.1; Р = 0.8); in group of the healthy donors: G/G = 0.45; G/C = 0.50; C/C = 0.05 (χ2 = 0.7; Р = 0.4).
In the patients with nasopharyngeal angiofibroma there was observed genotype CC of genetic marker С963T, increase in frequency of CC genotype to 40.0 % at the analysis of marker G405С, decrease in frequency of AA genotype up to 10.0 % and increase in frequency of GG genotype to 50.0 % at the analysis marker G-1154A.
Clinical trial identification
For evaluation of reaction of pyrosequencing we used systems of the genetic analysis PyroMark Q24.
All authors have declared no conflicts of interest.